Webb, David Htike, Z Swarbrick, D Brady, Emer Gray, Laura Biglands, J Gulsin, G Henson, J Khunti, K McCann, G Waller, H Webb, M Sargeant, J Yates, T Zaccardi, F Davies, Melanie A randomised, open label, active comparator trial assessing the effects of 26 weeks of Liraglutide or Sitagliptin on cardiovascular function in young obese adults with Type 2 diabetes <h3>Aim To compare the effects of a glucagon‐like peptide‐1 receptor agonist and a dipeptidyl peptidase‐4 inhibitor on magnetic resonance imaging‐derived measures of cardiovascular function.</h3> <h3> Materials and methods In a prospective, randomized, open‐label, blinded endpoint trial liraglutide (1.8 mg) and sitagliptin (100 mg) were compared in asymptomatic, non‐insulin treated young (aged 18‐50 years) adults with obesity and type 2 diabetes. The primary outcome was difference in circumferential peak early diastolic strain rate change (PEDSR), a biomarker of cardiac diastolic dysfunction 26 weeks after randomization. Secondary outcomes included other indices of cardiac structure and function, HbA1c and body weight.</h3> <h3> Results Seventy‐six participants were randomized (54% female, mean ± SD age 44 ± 6 years, diabetes duration 4.4 years, body mass index 35.3 ± 6.1 kg m<sup>−2</sup>), of whom 65% had ≥1 cardiovascular risk factor. Sixty‐one participants had primary outcome data available. There were no statistically significant between‐group differences (intention‐to‐treat; mean [95% confidence interval]) in PEDSR change (−0.01 [−0.07, +0.06] s<sup>−1</sup>), left ventricular ejection fraction (−1.98 [−4.90, +0.94]%), left ventricular mass (+1.14 [−5.23, +7.50] g) or aortic distensibility (−0.35 [−0.98, +0.28] mmHg<sup>−1</sup> × 10<sup>−3</sup>) after 26 weeks. Reductions in HbA1c (−4.57 [−9.10, −0.37] mmol mol<sup>−1</sup>) and body weight (−3.88 [−5.74, −2.01] kg) were greater with liraglutide. </h3> <h3> Conclusion There were no differences in cardiovascular structure or function after short‐term use of liraglutide and sitagliptin in younger adults with obesity and type 2 diabetes. Longer studies in patients with more severe cardiac dysfunction may be necessary before definitive conclusions can be made about putative pleiotropic properties of incretin‐based therapies.</h3> Cardiac magnetic resonance;Diastolic dysfunction;Liraglutide;Obesity;Peak early diastolic strain rate;Randomized controlled trial;Sitagliptin;Type 2 diabetes;Young adults 2020-04-03
    https://figshare.le.ac.uk/articles/journal_contribution/A_randomised_open_label_active_comparator_trial_assessing_the_effects_of_26_weeks_of_Liraglutide_or_Sitagliptin_on_cardiovascular_function_in_young_obese_adults_with_Type_2_diabetes/11955975